Study Reveals Declining COVID-19 Vaccine Efficacy Against Infection

The vaccines remain protective against serious disease and death.

Written byAnnie Melchor
| 2 min read
Black male doctor wearing a white lab coat and a mask vaccinates Black woman (also wearing a mask) in a medical office.

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

© ISTOCK.COM, SEVENTYFOUR

Post-COVID-19 vaccine immunity seems to be waning, according to a report published yesterday (August 24) in the US Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

The study followed more than 4,000 healthcare workers and other frontline essential workers across six states for 35 weeks, testing study participants weekly for SARS-CoV-2 infection, according to STAT. The majority of the participants received one of the three vaccines in use across the US—Pfizer, Moderna, and Johnson & Johnson—although most received the Pfizer vaccine. The study started collecting data on December 14, 2020, and as of early April 2021, it showed that the vaccines were approximately 90 percent effective at preventing symptomatic and asymptomatic SARS-CoV-2 infection.

Today’s report tracked the cohort through August 14—incorporating over four more months of data that include a time period in which the Delta variant swept the country—and found that overall, vaccine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white photograph of stephanie melchor

    Stephanie "Annie" Melchor got her PhD from the University of Virginia in 2020, studying how the immune response to the parasite Toxoplasma gondii leads to muscle wasting and tissue scarring in mice. While she is still an ardent immunology fangirl, she left the bench to become a science writer and received her master’s degree in science communication from the University of California, Santa Cruz, in 2021. You can check out more of her work here.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies